About three in four babies worldwide drink infant formula in the first six months of life, either as their sole source of nutrition or as a supplement to breastfeeding. But while formula provides an essential food for growing babies, it currently does not replicate the full nutritional profile of breast milk. 

That’s in part because human breast milk contains a unique blend of approximately 200 prebiotic sugar molecules that help prevent disease and support the growth of healthy gut bacteria. However, most of these sugars remain difficult if not impossible to manufacture. 

New research led by scientists at the University of California, Berkeley, and the University of California, Davis, shows how genetically engineered plants may help fill this gap. 

In a new study published June 13 in Nature Food, the study team reprogrammed plants’ sugar-making machinery to produce a diverse array of these human milk sugars, also called human milk oligosaccharides. The findings could lead to healthier and more affordable formula for babies, or more nutritious non-dairy plant milks for adults.

“Plants are these phenomenal organisms that take sunlight and carbon dioxide from our atmosphere and use them to make sugars. And they don't just make one sugar — they make a whole diversity of simple and complex sugars,” said senior author Patrick Shih, assistant professor of plant and microbial biology and an investigator at the Innovative Genomics Institute at UC Berkeley. “We thought, since plants already have this underlying sugar metabolism, why don't we try rerouting it to make human milk oligosaccharides?”

All complex sugars — including human milk oligosaccharides — are made from “building blocks” of simple sugars, called monosaccharides, which can be linked together to form an vast array of chains and branched chains. What makes human milk oligosaccharides unique are the specific set of linkages, or rules for connecting simple sugars together, that are found in these molecules.

Engineering plants to make human oligosaccharides

To convince plants to make human milk oligosaccharides, study first author Collin Barnum engineered the genes responsible for the enzymes that make these specific linkages. Working with Daniela Barile, David Mills and Carlito Lebrilla at UC Davis, he then introduced the genes into Nicotiana benthamiana plants, a close relative of tobacco.

The genetically modified plants produced 11 known human milk oligosaccharides, along with a variety of other complex sugars with similar linkage patterns.

“We made all three major groups of human milk oligosaccharides,” Shih said. “To my knowledge, no one has ever demonstrated that you could make all three of these groups simultaneously in a single organism.”

Barnum then worked to create a stable line of N. benthamiana plants that were optimized to produce a single human milk oligosaccharide called LNFP1.

“LNFP1 is a five-monosaccharide-long human milk oligosaccharide that is supposed to be really beneficial, but so far cannot be made at scale using traditional methods of microbial fermentation,” said Barnum, who completed the work as a graduate student at UC Davis. “We thought that if we could start making these larger, more complex human milk oligosaccharides, we could solve a problem that that industry currently can’t solve.”

Currently, a small handful of human milk oligosaccharides can be manufactured using engineered E. coli bacteria. However, isolating the beneficial molecules from other toxic byproducts is a costly process, and only a limited number of baby formulas include these sugars in their mixtures.

As part of the study, Shih and Barnum worked with collaborator Minliang Yang at North Carolina State University to estimate the cost of producing human milk oligosaccharides from plants at an industrial scale. They found that it would likely be cheaper than using microbial platforms.

“Imagine being able to make all the human milk oligosaccharides in a single plant. Then you could just grind up that plant, extract all the oligosaccharides simultaneously, and add that directly into infant formula,” Shih said. “There would be a lot of challenges in implementation and commercialization, but this is the big goal that we're trying to move towards.”

Additional authors include Bruna Paviani, Garret Couture, Chad Masarweh, Ye Chen, Yu-Ping Huang of UC Davis and Kasey Markel, UC Berkeley.

This work was supported in part by the National Institutes of Health (NIGMS T32 Training Program), the U.S. Department of Energy and the National Center for Complementary and Integrative Health (R00AT009573).

This article originally appeared on the UC Davis News website.